In AML, high levels of S100A8 [4] and S100A9 are correlated with poor overall survival predominantly in patients with myelomonocytic differentiation (M4, M5) [4, 5] and in de novo pediatric AML patients [4], whilst low S100A8 and S100A9 levels correlate with good prognosis in childhood AML with IDH1/2 mutations [6]. Here, S100A8 is linked to acute myeloid leukemia.